The patient Alex Lomas is taking a biological drug for Crohn’s disease, and he wants to know why the maker is trying to prevent disclosure of trial data that may well affect him
No takes yet. Share an insight, caveat, or question.
Alex Lomas (2013) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: